321 reports of this reaction
2.1% of all AGALSIDASE BETA reports
#10 most reported adverse reaction
WEIGHT DECREASED is the #10 most commonly reported adverse reaction for AGALSIDASE BETA, manufactured by Genzyme Corporation. There are 321 FDA adverse event reports linking AGALSIDASE BETA to WEIGHT DECREASED. This represents approximately 2.1% of all 15,654 adverse event reports for this drug.
Patients taking AGALSIDASE BETA who experience weight decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WEIGHT DECREASED is a less commonly reported adverse event for AGALSIDASE BETA, but still significant enough to appear in the safety profile.
In addition to weight decreased, the following adverse reactions have been reported for AGALSIDASE BETA:
The following drugs have also been linked to weight decreased in FDA adverse event reports:
WEIGHT DECREASED has been reported as an adverse event in 321 FDA reports for AGALSIDASE BETA. This does not prove causation, but indicates an association observed in post-market surveillance data.
WEIGHT DECREASED accounts for approximately 2.1% of all adverse event reports for AGALSIDASE BETA, making it a notable side effect.
If you experience weight decreased while taking AGALSIDASE BETA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.